Vivo Capital, LLC Q4 2017 Filing
Filed February 9, 2018
Portfolio Value
$466.9B
Holdings
30
Report Date
Q4 2017
Filing Type
13F-HR
All Holdings (30 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | ASNDAscendis Pharma | 1,766,832 | $70.8B | 15.16% | |
| 2 | —Biohaven Pharmaceutical Holding Company Ltd | 1,976,818 | $53.3B | 11.42% | |
| 3 | ACRSAclaris Therapeutics | 1,647,214 | $40.6B | 8.70% | |
| 4 | APLSApellis Pharmaceuticals, Inc. | 1,457,834 | $31.6B | 6.78% | |
| 5 | CDXSCodexis, Inc. | 3,054,825 | $25.5B | 5.46% | |
| 6 | CLDNEUREiger BioPharmaceuticals | 1,791,257 | $25.0B | 5.35% | |
| 7 | —Nabriva Therapeutics Plc | 4,074,190 | $24.4B | 5.22% | |
| 8 | —Aimmune Therapeutics, Inc. | 643,626 | $24.3B | 5.21% | |
| 9 | KALAKala Pharmaceuticals, Inc. | 1,158,911 | $21.4B | 4.59% | |
| 10 | —Advanced Accelerator Applications S.A. | 249,241 | $20.3B | 4.36% | |
| 11 | —Strongbridge Biopharma Plc | 2,452,397 | $17.8B | 3.81% | |
| 12 | VRNAVerona Pharma Plc | 1,492,951 | $17.7B | 3.80% | |
| 13 | —Kadmon Holdings, Inc. | 3,333,333 | $12.1B | 2.58% | |
| 14 | SELBUSDSelecta Biosciences, Inc. | 1,119,189 | $11.0B | 2.35% | |
| 15 | AMRSEURAmyris, Inc. | 2,826,711 | $10.6B | 2.27% | |
| 16 | —Sierra Oncology, Inc | 2,438,270 | $9.1B | 1.95% | |
| 17 | —Soleno Therapeutics, Inc. | 4,033,534 | $7.3B | 1.56% | |
| 18 | ZLABZai Lab LTD | 317,567 | $6.7B | 1.44% | |
| 19 | AUPHAurinia Pharmaceuticals Inc. | 1,213,290 | $5.5B | 1.18% | |
| 20 | RGNXRegenxbio Inc. | 164,403 | $5.5B | 1.17% | |
| 21 | —Foamix Pharmaceuticals Ltd. | 855,000 | $5.1B | 1.10% | |
| 22 | —Zogenix, Inc. | 105,000 | $4.2B | 0.90% | |
| 23 | —Agile Therapeutics, Inc. | 1,513,975 | $4.1B | 0.87% | |
| 24 | KALVKalVista Pharmaceuticals, Inc. | 300,325 | $2.9B | 0.63% | |
| 25 | —Trevena, Inc. | 1,728,000 | $2.8B | 0.59% | |
| 26 | CRSPCRISPR Therapeutics AG | 98,511 | $2.3B | 0.50% | |
| 27 | —Sunesis Pharmaceuticals, Inc. | 500,000 | $1.8B | 0.40% | |
| 28 | —BioPharmX Corporation | 13,799,944 | $1.5B | 0.33% | |
| 29 | —Akari Therapeutics Plc | 345,850 | $1.5B | 0.32% | |
| 30 | —Soleno Therapeutics, Inc. | 188,772 | $27.0M | 0.01% |